31 Mar 2026 | 5 Mins Read
Pharma stocks surge as India's GLP-1 market set to boom by 2030
Flipitmoney
India’s GLP-1 market, estimated at ₹1,000–1,200 crore in FY25, is expected to grow 5X to ₹5,000 crore by 2030, driven by type-2 diabetes (60–70% demand) and rising weight-loss use. The patent expiry of Semaglutide on March 20, 2026, could lead to a 40–50% price drop by FY27, positioning Sun Pharmaceuticals, Dr. Reddy's Laboratories, and Emcure Pharmaceuticals as key beneficiaries.